The Indian Journal of Chest Diseases and Allied Sciences

Register      Login

VOLUME 64 , ISSUE 2 ( April-June, 2022 ) > List of Articles


To End Tuberculosis, India must Embrace Innovation: Lessons from the ZeNix Trial Results

D. Behera

Citation Information : Behera D. To End Tuberculosis, India must Embrace Innovation: Lessons from the ZeNix Trial Results. Indian J Chest Dis Allied Sci 2022; 64 (2):63-64.

DOI: 10.5005/jp-journals-11007-0005

License: CC BY-NC 4.0

Published Online: 08-07-2022

Copyright Statement:  Copyright © 2022; The Author(s).


  1. World Health Organisation (WHO), 2020. Global Tuberculosis Report 2020. Available from: (Accessed January 14, 2022).
  2. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med 2020;382(10):893–902. DOI: 10.1056/NEJMoa1901814.
  3. Conradie F. High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid. IAS 2021, Berlin, Germany [Conference presentation].
  4. Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrugresistant tuberculosis: a multicenter, randomized controlled trial (the NExT Study). Am J Respir Crit Care Med 2022;205:1214–1227.
  5. Nyang'wa BT. TB-PRACTECAL trial results and next steps. Presented at the 52nd World Conference on Lung Health; 2021.
  6. Lange C, Barry III, CE, et al. Treatments of multidrug-resistant tuberculosis: Light at the end of the tunnel. Am J Respir Crit Care Med 2022;205:1142-1143.
  7. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis May 2022. WHO/UCN/TB/2022.2 © World Health Organization 2022
  8. Mallick JS, Nair P, Abbew ET, et al. Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review. Jac-antimicrobial Resistance. 2022 Apr;4(2):dlac029. DOI: 10.1093/jacamr/dlac029. PMID: 35356403; PMCID: PMC8963286.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.